CD44v6与COX-2在腮腺多形性腺瘤及癌在多形性腺瘤中的表达及临床意义

doi:10.19439/j.sjos.2019.04.015

摘要/Abstract

摘要： 目的探讨CD44v6与环氧合酶2（cyclooxygenase-2,COX-2）的表达与腮腺多形性腺瘤复发和恶化的相关性。方法采用免疫组织化学法检测19例正常腮腺组织、25例初发多形性腺瘤、15例第一次复发多形性腺瘤、15例第二次复发多形性腺瘤和13例癌在多形性腺瘤组织中CD44v6与COX-2的表达,采用SPSS 15.0软件包分析CD44v6与COX-2与腮腺多形性腺瘤复发和恶化的相关性。结果正常腮腺组织、初发多形性腺瘤、第一次复发多形性腺瘤、第二次复发多形性腺瘤与癌在多形性腺瘤中CD44v6阳性表达率分别为5.26%、44.00%、60.00%、93.37%和100.00%,COX-2阳性表达率分别为10.53%、40.00%、63.33%、93.37%和100.00%,各组CD44v6和COX-2阳性表达强度比较,差异有统计学意义（P<0.05）。正常腮腺组织中CD44v6和COX-2阳性表达率和表达强度显著低于其他各组（P<0.05）,初发多形性腺瘤与第一次复发多形性腺瘤组织中CD44v6阳性表达率和表达强度比较均无统计学差异（P>0.05）,2组COX-2表达强度比较无统计学差异（P>0.05）,但COX-2阳性表达率差异显著（P<0.05）;第二次复发多形性腺瘤组织中,CD44v6阳性表达率和表达强度以及COX-2表达强度显著高于第一次复发多形性腺瘤（P<0.05）,但2组COX表达阳性率无显著差异（P>0.05）;第二次复发多形性腺瘤组织与癌在多形性腺瘤组织中,CD44v6和COX-2阳性表达率和表达强度无统计学差异（P>0.05）。结论 CD44v6和COX-2能够通过协同作用,共同促进多形性腺瘤发生、侵袭、复发和恶化。

关键词: 腮腺, 多形性腺瘤, 癌在多形性腺瘤, CD44v6, 环氧合酶-2

Abstract: PURPOSE: To investigate the correlation between CD44v6 and cyclooxygenase-2(COX-2) expression and recurrence and deterioration of pleomorphic adenoma of parotid gland. METHODS: Immunohistochemistry was used to detect the expression of CD44v6 and COX-2 in 19 normal parotid tissues, 25 primary pleomorphic adenomas, 15 first recurrent pleomorphic adenoma, 15 second recurrent pleomorphic adenoma and 13 cancer in pleomorphic adenomas. The correlation between CD44v6 and COX-2 and the recurrence and deterioration of pleomorphic adenomas was evaluated using SPSS 15.0 software package. RESULTS: The positive expression rate of CD44v6 in normal parotid gland, primary pleomorphic adenoma, first recurrent pleomorphic adenoma, second recurrent pleomorphic adenoma and cancer was 5.26%, 44.00%, 60.00%, 93.37% and 100.00%, respectively;and the positive expression rate of COX-2 was 10.53%, 40.00%, 63.33%, 93.37% and 100.00%, respectively. There was significant difference in the positive expression intensity of CD44v6 and COX-2 among the groups (P<0.05). The positive expression rate and intensity of CD44v6 and COX-2 in normal parotid gland tissue were significantly lower than those in other groups (P<0.05). There was no significant difference in the positive expression rate and intensity of CD44v6 between primary pleomorphic adenoma and first recurrent pleomorphic adenoma (P>0.05). There was no significant difference in the expression intensity of COX-2 between the two groups (P>0.05), but the positive expression rate of COX-2 between the two groups was not significant(P>0.05). The positive expression rate and intensity of CD44v6 and COX-2 in the second recurrent pleomorphic adenoma were significantly higher than those in the first recurrent pleomorphic adenoma(P<0.05), but there was no significant difference between the two groups(P>0.05). CD44v6 in the second recurrent pleomorphic adenoma and cancer was significantly higher than that in the first recurrent pleomorphic adenoma(P<0.05). There was no significant difference in the expression rate and intensity of COX-2 (P>0.05). CONCLUSIONS: CD44v6 and COX-2 may play an important role in promoting occurrence, invasion, recurrence and deterioration of pleomorphic adenoma through synergistic action.

Key words: Parotid gland, Pleomorphic adenoma, Cancer in pleomorphic adenoma, CD44v6, Cyclooxygenase-2

中图分类号:

R739.8

胡赟, 张艳胜. CD44v6与COX-2在腮腺多形性腺瘤及癌在多形性腺瘤中的表达及临床意义[J]. 上海口腔医学, 2019, 28(4): 412-416.

HU Yun, ZHANG Yan-sheng. Expression of CD44v6 and COX-2 in pleomorphic adenomas and carcinomas of parotid gland[J]. Shanghai Journal of Stomatology, 2019, 28(4): 412-416.

参考文献

[1] 许壮勇, 曾向廷, 林黛英, 等. CT及MRI在腮腺腺泡细胞癌与多形性腺瘤鉴别诊断中的价值[J]. 临床放射学杂志, 2017, 36(7): 947-951.
[2] 吴俊, 依沙克江·买买提, 买买提吐逊·吐尔地. 腮腺浅叶多形性腺瘤包膜外切除术与浅叶切除术预后的比较[J]. 广东医学, 2016, 37(24): 3715-3717.
[3] 邓刚, 李晓光, 何悦, 等. 复发性腮腺多形性腺瘤的手术治疗及并发症预防[J]. 中国口腔颌面外科杂志, 2017, 15(3): 227-230.
[4] Soslow RA, Dannenberg AJ, Rush D, et al.COX‐2 is expressed in human pulmonary, colonic, and mammary tumors[J]. Cancer, 2015, 89(12): 2637-2645.
[5] Todaro M, Gaggianesi M, Catalano V, et al.CD44v6 is a marker of constitutive and reprogrammed cancer stem cells driving colon cancer metastasis[J]. Cell Stem Cell, 2014, 14(3): 342-356.
[6] 吴秉铨. 免疫组织化学病理诊断[M]. 北京: 科学技术出版社, 2007.
[7] 倪洪早, 张芸, 崔晨晨, 等. 沉默LASP-1对人胶质瘤细胞的黏附、迁移和侵袭能力的影响及其机制[J]. 中华实验外科杂志, 2016, 33(4): 986-988.
[8] 黄丽珊, 卢碧燕, 李仲均, 等. CD44v6在卵巢上皮性肿瘤中的表达及其对卵巢癌细胞株侵袭和迁移能力的影响[J]. 现代肿瘤医学, 2016, 24(4): 625-629.
[9] Zaiden M, Feinshtein V, David A.Inhibition of CD44v3 and CD44v6 function blocks tumor invasion and metastatic colonization[J]. J Contr Release, 2017, 257(1): 10-20.
[10] 黎昌学, 朱声荣, 陈卫民, 等. 基质金属蛋白酶2、CD44v6在腮腺多形性腺瘤中的表达研究[J]. 临床口腔医学杂志, 2005, 21(4): 217-219.
[11] Franchi A, Moroni M, Paglierani M, et al.Expression of CD44 standard and variant isoforms in parotid gland and parotid gland tumours[J]. J Oral Pathol Med, 2010, 30(9): 564-568.
[12] Fu YG, Sung JJ, Wu KC, et al.Inhibition of gastric cancer-associated angiogenesis by antisense COX-2 transfectants[J]. Cancer Letters, 2005, 224(2): 243-252.
[13] 周宁, 程娟, 钟毅, 等. RNA结合蛋白HuR调控前列腺癌细胞活力机制的研究[J]. 中华肿瘤防治杂志, 2016, 23(5): 297-303.
[14] 张慧, 木合塔尔·霍加. 环氧化酶-2及其抑制剂与口腔颌面部上皮性肿瘤的关系[J]. 新医学, 2010, 41(11): 762-764.
[15] Basudhar D, Glynn SA, Greer M, et al.Coexpression of NOS2 and COX2 accelerates tumor growth and reduces survival in estrogen receptor-negative breast cancer[J]. PNAS, 2017, 114(49): 13030-13035.
[16] Sakurai K, Urade M, Noguchi K, et al.Increased expression of cyclooxygenase‐2 in human salivary gland tumors[J]. Pathol Int, 2001, 51(10): 762-769.
[17] 朱玉红, 张树华, 吕增华. 胃癌组织中COX-2、CD44v6和MMP-9蛋白表达及意义[J]. 山东医药, 2009, 49(7):57-59.
[18] 马天有, 刘文康, 楚雍烈, 等. 食管鳞癌中COX-2和CD44v6的表达及其临床意义[J]. 现代肿瘤医学, 2006, 14(11):1379-1382.